MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Parkinson’s disease patients may be at higher risk of Covid-19 mortality

    M. Salari, M. Etemadifar, S. Tehrani Fateh, Z. Aminzade (Tehran, Islamic Republic of Iran)

    Objective: To investigate the Covid-19 mortality in Parkinson’s disease (PD) patients. Background: PD patients may be at increased risk of Covid-19 mortality due to the…
  • MDS Virtual Congress 2021

    Cognitive impairment in patients with Alzheimer’s disease and Parkinson’s disease

    O. Chyniak (Sumy, Ukraine)

    Objective: To compare the results of a neuropsychological study in patients with Alzheimer's disease and Parkinson's disease. Background: Recently, Parkinson's disease (PD) is increasingly considered…
  • MDS Virtual Congress 2021

    Emotional and cognitive information processing in obstacle negotiation in patient with Parkinson’s disease and freezing

    S. Mezzarobba, M. Grassi, E. Pelosin, P. Manganotti, P. Bernardis (Genova, Italy)

    Objective: We used emotional (images from the International Affective Picture System - IAPS)1 and cognitive inputs(visual perturbation in a stepping-over-the-obstacle task) with the aim to…
  • MDS Virtual Congress 2021

    A prospective study of Parkinson’s disease dementia – defining neuropsychological features

    E. Stefanova, LJ. Ziropadja, T. Stojkovic, V. Markovic, I. Stankovic, I. Petrovic, N. Dragasevic Miskovic, M. Svetel, V. Kostic (Belgrade, Serbia)

    Objective: To identify neuropsychological predictors of conversion to dementia (PDD) in our cohort of Parkinson’s disease (PD) patients. Background: The heterogeneity of PD cognitive disorders…
  • MDS Virtual Congress 2021

    GP2: training the next generation of Parkinson’s disease genetics researchers – wherever they are in the world

    S. Dey, A. Noyce, C. Bale, M. Kuhl, H. Leonard, P. Lewis, S. Stott, S. Adams, A. Martinez-Carrasco, B. Stecher, S. Bandres-Ciga, G. Genetics Program (London, United Kingdom)

    Objective: To establish a virtual ‘center of excellence’ with resources and expertise to serve the training needs of the Global Parkinson’s Genetics Program (GP2; www.gp2.org)…
  • MDS Virtual Congress 2021

    Monogenic Portal of the Global Parkinson’s Genetics Program (GP2)

    SY. Lim, LM. Lange, H. Madoev, KR. Kumar, AH. Tan, M. Avenali, P. Heutink, EJ. Vollstedt, K. Lohmann, N. Mencacci, C. Klein, EM. Valente (Kuala Lumpur, Malaysia)

    Objective: To support the efforts of the Global Parkinson’s Genetics Program (GP2, http://gp2.org/) Monogenic Hub, by developing an easy-to-use online platform for case/family submission. Background:…
  • MDS Virtual Congress 2021

    Stratified genome-wide association study revealed novel interactions for the top hit Parkinson’s disease loci.

    K. Senkevich, S. Bandres-Ciga, E. Yu, L. Krohn, Z. Gan-Or (Montreal, Canada)

    Objective: To identify genetic modifiers and interactors that may modulate known risk variants in the SNCA, TMEM175 and MAPT loci in Parkinson’s disease (PD). Background:…
  • MDS Virtual Congress 2021

    Antioxidants in foods: A Primary Potential remedy to Neurodegeneration.

    B. Adebisi (Osogbo, Nigeria)

    Objective: The aim of the research is to establish the plausibility of reducing the effects of the actions of reactive oxygen species, produced by glutamate…
  • MDS Virtual Congress 2021

    The gut microbiome in Parkinson’s disease: longitudinal insights into disease progression and the use of device-assisted therapies.

    M. Lubomski, X. Xu, A. Holmes, S. Mueller, J. Yang, C. Sue, R. Davis (St Leonards, Australia)

    Objective: We investigated the temporal stability of gut microbiome (GM) profiles from Parkinson’s disease (PD) patients initiating device-assisted therapies (DAT) and in a separate cohort…
  • MDS Virtual Congress 2021

    RNA Editing in Parkinson’s Disease Shows Changes in Mitochondrial and Manganese-Binding Pathways in Multiple Brain Regions

    A. Thele, O. Gardner, J. Vance, A. Griswold, J. Young, M. Pericak-Vance, W. Scott, E. Martin, W. Wang, D. Dykxhoorn, C. Petito, G. Beecham, D. Mash, S. Sivasankaran (Miami, USA)

    Objective: To identify RNA editing alterations associated with Parkinson’s disease (PD) in the Dorsal Motor Nucleus of the Vagus (DMV), Substantia Nigra (SN), and Cingulate…
  • « Previous Page
  • 1
  • …
  • 85
  • 86
  • 87
  • 88
  • 89
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley